Skip to main content
ELI LILLY & Co logo

ELI LILLY & Co — Investor Relations & Filings

Ticker · LLY ISIN · US5324571083 LEI · FRDRIPF3EKNDJ2CQJL29 US Manufacturing
Open in API
Filings indexed 3,870 across all filing types
Latest filing 2026-05-20 Capital/Financing Update
Country US United States of America
Listing US LLY

About ELI LILLY & Co

https://www.lilly.com/

Eli Lilly and Company is a global, research-based medicine company that discovers, develops, manufactures, and sells pharmaceutical products. The company focuses on creating treatments in key therapeutic areas, including diabetes, obesity, immunology, oncology, and neuroscience. Leveraging biotechnology and chemistry, it develops medicines for some of the world's most significant health challenges. Historically known for the commercialization of insulin, the company continues to be a major provider of therapies for chronic diseases. Its stated purpose is to unite caring with discovery to create medicines that make life better for people around the world.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 98% confidence The document is a Form 8-K “Current Report” filed under the Securities Exchange Act, specifically reporting the completion of Eli Lilly’s offering of various floating rate and fixed rate notes. This constitutes a financing activity (debt issuance), not an earnings release or management discussion. Therefore it falls under the Capital/Financing Update category.
2026-05-20 English
SD
Report Publication Announcement Classification · 78% confidence The document is a short SEC “Form SD” specialized disclosure (Conflict Minerals) filing for the year ended December 31, 2025. It contains no substantive financial statements; rather, it states that the detailed Conflict Minerals Report is attached as an exhibit and available via a link. Under the “Menu vs Meal” rule, such brief filings that announce publication of a report and provide a link or exhibit are classified as Report Publication Announcements (RPA).
2026-05-11 English
424B2 - ELI LILLY & Co (0000059478) (Filer)
Capital/Financing Update Classification · 89% confidence The document is a prospectus supplement filed under Rule 424(b)(2) describing the terms of a multi-billion dollar debt offering (floating and fixed rate notes), interest rates, redemption provisions, use of proceeds, underwriting details, etc. This is a financing activity disclosure, not a regular financial report, management change, or regulatory certification. It falls under Capital/Financing Update.
2026-05-08 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is a Form 8-K “Current Report” under the Securities Exchange Act, specifically Item 5.07 “Submission of Matters to a Vote of Security Holders.” It provides detailed vote tallies for director elections and proposals at the 2026 Annual Meeting, which constitutes an official declaration of voting results. This matches the “Declaration of Voting Results & Voting Rights Announcements” category (DVA).
2026-05-07 English
FWP - ELI LILLY & Co (0000059478) (Subject)
Capital/Financing Update Classification · 92% confidence The document is a Free Writing Prospectus and Pricing Term Sheet filed under Rule 433 for a $9 billion notes offering by Eli Lilly and Company. It details the terms of multiple tranches of debt securities, including interest rates, maturities, redemption provisions, and CUSIPs. This is clearly a capital‐raising/financing activity notice, not a full annual or interim report, governance filing, or simple publication announcement. Therefore, it best fits the Capital/Financing Update category (CAP).
2026-05-06 English
424B2 - ELI LILLY & Co (0000059478) (Filer)
Capital/Financing Update Classification · 90% confidence The document is a preliminary prospectus supplement filed under Rule 424(b)(2) related to an offering of floating and fixed rate notes by Eli Lilly and Company. It details the terms of the note issuance, interest rates, maturities, use of proceeds, underwriting, and related financing provisions. This is a capital markets fundraising document, not an annual or interim report, management change notice, or earnings release. It falls squarely under a financing update for debt issuance.
2026-05-06 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.